How Much is SUDEP Known by Patients by Epilepsy?

Objective:Sudden unexpected death in epilepsy (SUDEP) is the most common cause of death in patients with epilepsy. The issue of informing every epilepsy patient and/or their relatives about SUDEP remains controversial. We evaluated the level of knowledge about SUDEP in patients with epilepsy.Methods:Patients were asked whether they knew about seizure risks and wanted to be informed about seizure risks, whether they had heard of SUDEP before and if they did, from whom or where they had heard about it, and seizure triggers. In addition, the patient’s relatives were asked about what to do or not to do during the seizure.Results:We included 80 patients with epilepsy in the study, of which 45 were female (56.2%) and 35 were male (44.8%). Twenty-five (31.2%) patients stated that they had not received any information about epilepsy. Only nine (11.2%) patients stated that they heard about SUDEP, six of them learned from the internet, three from a doctor, two of them said it happened to their relatives, and 69 (86.2%) patients thought that epilepsy patients should definitely be informed about this issue.Conclusion:Our findings indicate that the level of knowledge about SUDEP among epilepsy patients is quite low. Even though learning SUDEP caused uneasiness in patients, it was observed that patients wanted to learn this information. More efforts should be made to inform patients with epilepsy about epilepsy and its risks and SUDEP

COVID-19 Vaccine Take-up Rate, Safety and Tolerability in Patients with Epilepsy

Objective:Although vaccines are considered safe for most people, patients with some chronic diseases have been very hesitant to get vaccinated, especially at the initial stages of vaccination. We conducted a survey among patients with epilepsy (PWE) who are currently experiencing hesitations, aiming to investigate the vaccination rates against Coronavirus disease-2019 (COVID-19) and the side effects emerged in vaccinated patients.Methods:Two hundred nineteen PWE were questioned during a routine outpatient follow-up through previously prepared questionnaires that contained questions about patients’ demographic features, information about the vaccination status, and its adverse effects.Results:We included 219 PWE in the study of which 112 (51.1%) were female and 107 (48.8%) were male. One hundred eighty patients (82.1%) had been vaccinated at least once, 75% of the patients preferred two doses of BNT162b2 mRNA COVID-19 vaccine, 9.4% of the patients preferred two doses of Sinovac’s inactivated vaccine, 6.1% of the patients preferred three doses of Sinovac, and 9.4% of the patients preferred Sinovac and BNT162b2 vaccines. Seventy-seven (42.7%) patients reported that they experienced side effects after vaccination whereas ten patients (5.5%) reported worsening of their seizures after vaccination; one person stated that she/he was hospitalized in the intensive care unit due to status epilepticus.Conclusion:Generally, the tolerance of COVID-19 vaccines has progressed with mild side effects in most cases, which is consistent with previous studies in the general population, similarly no serious and previously unreported side effects were found in our study. Our study showed that COVID-19 vaccines are well-tolerated and safe for seizures in PWE

Epileptic seizures in cerebral venous sinus thrombosis: Subgroup analysis of VENOST study

Purpose: The aim of this study is to evaluate the presence and prognostic impact of early seizures in cerebral venous sinus thrombosis patients (CVST).Method: VENOST is a retrospective and prospective national multicenter observational study. CVST patients with or without epileptic seizures (ES) were analyzed and compared in terms of demographic and imaging data, causative factors, clinical variables, and prognosis in a total of 1126 patients.Results: The mean age of the patients in the ES group was 39.73 +/- 12.64 and 40.17 +/- 14.02 years in the non-ES group (p > 0.05). Epileptic seizures were more common (76.6 %) in females (p < 0.001). Early ES occurred in 269 of 1126 patients (23.9 %). Epileptic seizures mainly presented in the acute phase (71.4 %) of the disease (p < 0.001). Majority of these (60.5 %) were in the first 24 h of the CVST. The most common neurological signs were focal neurologic deficits (29.9 %) and altered consciousness (31.4 %) in the ES group. Superior sagittal sinus (SSS) and cortical veins (CV) involvement were the most common sites of thrombosis and the mostly related etiology were found puerperium in seizure group (30.3 % vs 13.9 %). Patients with seizures had worse outcome in the first month of the disease (p < 0.001) but these did not have any influence thereafter.Conclusions: In this largest CVST cohort (VENOST) reported female sex, presence of focal neurological deficits and altered consciousness, thrombosis of the SSS and CVs, hemorrhagic infarction were risk factors for ES occurrence in patients with CVST

Epileptic seizures in cerebral venous sinus thrombosis: Subgroup analysis of VENOST study

Purpose: The aim of this study is to evaluate the presence and prognostic impact of early seizures in cerebral venous sinus thrombosis patients (CVST). Method: VENOST is a retrospective and prospective national multicenter observational study. CVST patients with or without epileptic seizures (ES) were analyzed and compared in terms of demographic and imaging data, causative factors, clinical variables, and prognosis in a total of 1126 patients. Results: The mean age of the patients in the ES group was 39.73 +/- 12.64 and 40.17 +/- 14.02 years in the non-ES group (p > 0.05). Epileptic seizures were more common (76.6 %) in females (p < 0.001). Early ES occurred in 269 of 1126 patients (23.9 %). Epileptic seizures mainly presented in the acute phase (71.4 %) of the disease (p < 0.001). Majority of these (60.5 %) were in the first 24 h of the CVST. The most common neurological signs were focal neurologic deficits (29.9 %) and altered consciousness (31.4 %) in the ES group. Superior sagittal sinus (SSS) and cortical veins (CV) involvement were the most common sites of thrombosis and the mostly related etiology were found puerperium in seizure group (30.3 % vs 13.9 %). Patients with seizures had worse outcome in the first month of the disease (p < 0.001) but these did not have any influence thereafter. Conclusions: In this largest CVST cohort (VENOST) reported female sex, presence of focal neurological deficits and altered consciousness, thrombosis of the SSS and CVs, hemorrhagic infarction were risk factors for ES occurrence in patients with CVST.WOS:0005375741000192-s2.0-85083703251PubMed: 3235381

The effect of sleep disorders on quality of life in patients with epilepsy: A multicenter study from Turkey

Objective: We aimed to investigate sleep disorders in patients with epilepsy (PWE) and to investigate the effects of sleep disorders on quality of life. Methods: In our multicenter study conducted in Turkey, 1358 PWE were evaluated. The demographic and clinical data of the patients were recorded. The Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and Quality of Life in Epilepsy Inventory-10 (QOLIE-10) were administered. Results: The mean age of 1358 patients was 35.92 ± 14.11 (range, 18–89) years. Seven hundred fifty-one (55.30 %) were women. Some 12.7 % of the patients had insomnia (ISI > 14), 9.6 % had excessive daytime sleepiness (ESS > 10), 46.5 % had poor sleep quality (PSQI > 5), and 354 patients (26.1 %) had depressive symptoms (BDI > 16). The mean QOLIE-10 score was 22.82 ± 8.14 (10–48). Resistant epilepsy was evaluated as the parameter with the highest risk affecting quality of life Adjusted odds ratio (AOR = 3.714; 95 % confidence interval (CI): [2.440–5.652] < 0.001)). ISI (AOR = 1.184; 95 % CI: [1.128–1.243]; p < 0.001), ESS (AOR = 1.081; 95 % CI: [1.034–1.130]; p < 0.001), PSQI (AOR = 0.928; 95 % CI: [0.867 – 0.994]; p = 0.034), BDI (AOR = 1.106; 95 % CI: [1.084–1.129]; p < 0.001), epilepsy duration (AOR = 1.023; 95 % CI: [1.004–1.041]; p = 0.014), were determined as factors affecting quality of life. Significance: Sleep disorders are common in PWE and impair their quality of life. Quality of life can be improved by controlling the factors that may cause sleep disorders such as good seizure control, avoiding polypharmacy, and correcting the underlying mood disorders in patients with epilepsy